Deficiency of SIRT3 reportedly aggravates lipid deposition and FAO dysfunction in cisplatin-mediated AKI, whereas the activation of SIRT3 improves the level of FAO by deacetylation of liver kinase B1 (LKB1) and activation of AMPK, which meets energy requirement and reduces the kidney damage [68]. This evidence concerns the gene STK11 and acute kidney injury.